Sapio Sciences Rings in 2023 With Major Investment from GHO Capital

Sapio Sciences Rings in 2023 With Major Investment from GHO Capital

GHO Capital, the European specialist investor in global healthcare, has announced its investment in leading low-code/no-code informatics platform, Sapio Sciences.

Baltimore, MD – Jan 6, 2023 – The London-based leading specialist healthcare investment advisor, Global Healthcare Opportunities, also called GHO Capital Partners LLP, has announced its investment in Sapio Sciences, a high-growth integrated lab informatics platform.

Lab informatics platforms are gaining momentum today, with more modern laboratories striving to accelerate their R&D. With GHO’s backing to scale it, Sapio Sciences hopes the company will evolve as a formidable player in the lab informatics market. 

Kevin Cramer, Chief Scientist and CEO at Sapio, said of GHO’s recent investment decision, “As lab workflows become increasingly complex and the volume of data increases, the management, and interrogation of that data becomes even more vital. Over the last eighteen years, Sapio has built a uniquely flexible, scalable, unified, and easy-to-use informatics platform developed specifically to address the deficiencies of current processes. We are proud to have GHO partner with us to support our next transformational steps as a company.”

Launched in 2004, Sapio Sciences is a US-based state-of-the-art lab informatics platform committed to transforming and speeding up life science R&D for biopharma, CROs, and clinical labs. 

This unified low-code/no-code platform offers various lab software products, such as its high-end scalable Electronic Lab Notebook (ELN), Laboratory Information Management System (LIMS), and Software Data Management (SDMS) software.

Sapio helps digital labs address all challenges they face while breaking through data silos and driving efficiency in their laboratory operations.

Sapio’s collaborative LIMS system allows multiple researchers to work on the same workflow simultaneously while also enabling rapid implementation of their workflow processes.

It’s the only informatics platform that provides digital labs with integrated ELN, LIMS, and SDMS with powerful data capture and searching tools.

Allowing laboratories to centralize data once siloed in multiple systems and making them effortlessly searchable and shareable among departments, Sapio streamlines the scientific discovery process.

With Sapio LIMS’s fully configurable technology and workflow templates, projects can be accomplished in a fraction of the time and cost of a standard lab management project. 

Validated by a broad and loyal customer base, including blue-chip companies across the USA with additional footholds in Japan and Europe, Sapio continues to help drive innovation in the ever-evolving lab informatics and pharmaceutical landscape. 

GHO’s investment, combined with its unrivaled experience, will support Sapio to drive growth for the company while facilitating its product development, says the private equity firm.

In addition, the firm’s investment into Sapio’s Commercial function and Business Development will help it establish a go-to-market strategy, thus uncovering significant white space in the market. 

To quote the Partners at GHO Capital, “The trend towards adopting lab informatics solutions is accelerating. Sapio represents a perfect opportunity to support a high-growth, profitable company with a uniquely scalable SaaS business model, operating in attractive markets that are underpenetrated and desperate for innovation. Working in lockstep with Kevin, we look forward to building upon Sapio’s best-in-class profile and unlocking the multiple expansion opportunities to scale up and internationalize the business, delivering life-changing products to market faster.”

Backed by eighteen years of experience, Sapio Sciences continues to remain a trusted and unbiased partner to its global clientele. 

Interested parties can learn more about Sapio Sciences by visiting

Media Contact
Company Name: Sapio Sciences LLC
Contact Person: Jim Zito
Email: Send Email
Phone: +1-410-800-4620
Address:400 East Pratt Street St 800
City: Baltimore
State: MD
Country: United States

Source: Financial Content

Previous post CD BioSciences Developed Genomic Monitoring and Analysis Based on Drosophila Research Projects
Next post Carmine Therapeutics to Present at Biotech Showcase™ 2023